ClinConnect ClinConnect Logo
Search / Trial NCT06490250

Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients

Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jun 29, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Exercise Capacity Pulmonary Function Quality Of Life

ClinConnect Summary

This clinical trial is looking to see how two different exercise programs can help patients with hypertrophic cardiomyopathy, a condition where the heart muscle is thicker than normal. The researchers want to compare the effects of inspiratory muscle training (IMT), which helps strengthen the muscles you use to breathe, with Baduanjin exercises, a form of gentle movement and stretching. The goal is to find out which program improves lung function, exercise ability, and overall quality of life for these patients.

To participate, you need to be over 18 years old and have a thickening of the heart muscle that is noticeable on an ultrasound or MRI. You should also be stable in your condition, meaning you don’t have any severe heart issues or other serious health problems. If you join the study, you’ll be placed in one of three groups: one will do the IMT exercises twice a day for eight weeks, while another will practice Baduanjin exercises three times a week. There will be regular check-ins to support you throughout the program. This trial is an opportunity to explore new ways to improve health and well-being for those living with this heart condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
  • Clinically and hemodynamically stable (patients with NYHA Class I and II)
  • Patients over 18 years of age
  • Patients who provide informed consent
  • Exclusion Criteria:
  • Acute decompensated heart failure
  • Decreased ejection fraction (\<40%)
  • Unstable angina pectoris
  • Significant coronary artery disease (CAD)
  • Severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/m²)
  • Uncontrolled hypertension (despite medication)
  • Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
  • Severe neurological disorders causing autonomic dysfunction
  • Cognitive impairment that prevents communication
  • Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems

About Istanbul University Cerrahpasa

Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.

Locations

Istanbul, , Turkey

Patients applied

0 patients applied

Trial Officials

Rengin Demir, Prof

Study Director

Istanbul University-Cerrahpasa (IUC) Cardiology Institute

Veysel Oktay, Assoc Prof

Study Chair

Istanbul University-Cerrahpasa (IUC) Cardiology Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported